At a Glance
AI-generated8-K
On March 24, 2026, CytoDyn Inc. and the holders of two secured convertible promissory notes (each with initial principal of $28.5 million) agreed to extend each note's maturity by 36 months to April 5, 2029 and April 23, 2029, respectively. In consideration, the company will make monthly payments totaling $1,000,000 in common stock shares to the noteholders and reduce the annual interest rate on each note to 5%.—
Market Cap
—
Revenue
—
Net Income
Employees9
Fundamentals
How The Business Makes Money
CytoDyn Inc. operates as a clinical-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor in the areas of human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), oncology, and such as coronavirus disease (COVID-19). It is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001175680
ISINUS23283M1018
CUSIP23283M101
Phone360 980 8524
Address1111 Main Street, Vancouver, WA, 98660, US
SEC EDGAR